Guideline for pharmacological treatment of schizophrenia 2022
- PMID: 39587785
- PMCID: PMC11666347
- DOI: 10.1002/npr2.12497
Guideline for pharmacological treatment of schizophrenia 2022
Conflict of interest statement
The guideline creation committee made every effort to avoid actual or potential conflicts of interest to enable its members to perform their duties in a neutral and fair manner. All members and academic societies involved in guideline creation disclosed potential or actual conflicts of interest. The disclosure criteria were set according to the “Guidance on eligibility criteria for participation in the development of clinical practice guidelines” by the Japanese Association of Medical Sciences, with the target period from January 1, 2019, to December 31, 2021.
Information on the conflicts of interest of the members and organizations of the Japanese Society of Neuropsychopharmacology and Japanese Society of Clinical Neuropsychopharmacology, which created the guideline, is provided at the end of this document.
None.
Similar articles
-
Relationships Between Adherence to Guideline Recommendations for Pharmacological Therapy Among Clinicians and Psychotic Symptoms in Patients With Schizophrenia.Int J Neuropsychopharmacol. 2023 Aug 29;26(8):557-565. doi: 10.1093/ijnp/pyad037. Int J Neuropsychopharmacol. 2023. PMID: 37381793 Free PMC article.
-
Effectiveness of a treatment guideline for schizophrenia in adolescents: Lessons from a middle-income country.Aust N Z J Psychiatry. 2018 Feb;52(2):192-199. doi: 10.1177/0004867417726581. Epub 2017 Aug 23. Aust N Z J Psychiatry. 2018. PMID: 28831809 Clinical Trial.
-
[Clinical guidelines for the management of schizophrenia: Pharmacological and psychological interventions (III)].Psychiatriki. 2018 Oct-Dec;29(4):303-315. doi: 10.22365/jpsych.2018.294.303. Psychiatriki. 2018. PMID: 30814040 Greek, Modern.
-
Guideline for the pharmacotherapy of treatment-resistant schizophrenia. Royal College of Psychiatrists of Thailand.J Med Assoc Thai. 2000 Jun;83(6):579-89. J Med Assoc Thai. 2000. PMID: 10932483 Review.
-
Non-pharmacological biological therapies in schizophrenia.Neuropsychopharmacol Hung. 2011 Dec;13(4):233-8. Neuropsychopharmacol Hung. 2011. PMID: 22184192 Review.
Cited by
-
Awareness and management of cognitive impairment associated with schizophrenia in psychiatrists and patients: Results from a cross-sectional survey.Schizophr Res Cogn. 2025 Jun 27;42:100375. doi: 10.1016/j.scog.2025.100375. eCollection 2025 Dec. Schizophr Res Cogn. 2025. PMID: 40678008 Free PMC article.
References
-
- Okuma T. (original author), Modern clinical psychiatry. In: 12th Edition Revision Committee , editor. Modern clinical psychiatry. 12th ed. Tokyo: Kanehara Shuppan; 2013.
-
- Japanese Society of Schizophrenia Research (editor‐in‐chief) . In: Fukuda M, Itokawa M, Murai T, Kasai K, editors. Schizophrenia. Tokyo: Igaku Shoiin; 2013.
-
- American Psychiatric Association (original author) , Japanese Society of Psychiatry and Neurology (editor‐in‐chief of Japanese terminology) , Takahashi S, Ohno Y (supervision of translation), Someya T, Kamba S, Ozaki N, Mimura M, et al. (trans.): DSM‐5 diagnostic and statistical manual of mental disorders, Tokyo: Igaku Shoin, 2014.
-
- Toru M, Nakane Y, Komiyama M, Okazaki Y, Okubo Y. (supervision of translation): ICD‐10 mental and behavioral disorders–clinical description and diagnostic guidelines New Revised Edition, Tokyo: Igaku Shoin, 2005.
LinkOut - more resources
Full Text Sources